![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
Case 2: Olaparib in BRCA-Mutated Ovarian Cancer (Targeted Oncology) View |
![]() |
Case 2: Newly Diagnosed Ovarian Cancer, gBRCA-Mutated (Targeted Oncology) View |
![]() |
Case 2: Maintenance in BRCA1/2wt, HR-Proficient Ovarian Cancer (Targeted Oncology) View |
![]() |
Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer (OncLive) View |
![]() |
Olaparib Maintenance for Recurrent Ovarian Cancer (OncLive) View |
![]() |
Results from phIII SOLO1 trial in BRCAm ovarian cancer (ecancer) View |
![]() |
Case 2: Primary Treatment Options (Targeted Oncology) View |
![]() |
Optimizing BRCA Testing in Advanced Ovarian Cancer (OncLive) View |
![]() |
Olaparib: An opportunity for personalised medicine in BRCA-related ovarian cancer (EMJ) View |
![]() |
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer (ecancer) View |